Cargando…
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation
BACKGROUND: The reported antitumor activity of the BET family bromodomain inhibitors has prompted the development of inhibitors against other bromodomains. However, the human genome encodes more than 60 different bromodomains and most of them remain unexplored. RESULTS: We report that the bromodomai...
Autores principales: | Garcia-Carpizo, Veronica, Ruiz-Llorente, Sergio, Sarmentero, Jacinto, Graña-Castro, Osvaldo, Pisano, David G., Barrero, Maria J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992658/ https://www.ncbi.nlm.nih.gov/pubmed/29884215 http://dx.doi.org/10.1186/s13072-018-0197-x |
Ejemplares similares
-
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation
por: García-Carpizo, Verónica, et al.
Publicado: (2016) -
The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies
por: Zhu, Yu, et al.
Publicado: (2023) -
Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors
por: Crawford, McKenna C., et al.
Publicado: (2023) -
Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300
por: Williams, Lynn M., et al.
Publicado: (2020) -
CREBBP and EP300 mutational spectrum and clinical presentations in a cohort of Swedish patients with Rubinstein–Taybi syndrome
por: Wincent, Josephine, et al.
Publicado: (2015)